View Clinical Trial (Medical Research Study)
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring - NCT00707512-26505(Clinical Trial 229427)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
200 Pinecrest Plaza, Morgantow |
|
State:
|
|
WV |
| Zip Code: |
|
26505 |
| Conditions: |
|
Crohn's Disease |
| Purpose: |
|
The purpose of this study is to determine the incidence and pattern of serious infections,
malignancies, and other serious adverse events in patients with Crohn's Disease(CD) treated
with TYSABRI® (Natalizumab)
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- CD patients prescribed TYSABRI® within the TOUCH prescribing program must be enrolled
prior to their 6th infusion of TYSABRI®
Exclusion Criteria: |
|
|
|
| Study is available at: |
|
There may be multiple sites in this clinical trial. Please contact United BioSource Corporation
200 Pinecrest Plaza, Morgantown, WV 26505
United States
Primary Contact:
Contact
Email: LSKC_CD_INFORM@unitedbiosource.com
Phone: 888-613-7542 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|